Related Experiment Video
Updated: May 13, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Prostate cancer vaccines
Agnieszka Michael1, Kate Relph, Nicola Annels
1Oncology Group, Faculty of Health & Medical Sciences, Leggett Building, University of Surrey, Guildford, GU2 7WG, UK. a.michael@surrey.ac.uk
Abstract:
In 2010, the US FDA approved the first therapeutic cancer vaccine for the treatment of castration refractory prostate cancer - sipuleucel-T. Prostate cancer is an ideal model for cancer vaccine development based on the ready demonstration of humoral and cellular immunity to a range of cancer antigens as well as often slow progression which means that patients who are otherwise well may have a radiologically evaluable minor progression, after conventional treatment and can undergo vaccine therapy over sufficient periods of time, so as to allow the generation of a robust antitumor response. The association of prostate cancer with one of the few serum cancer biomarkers in general use has also allowed assessment of response and risk stratification of patients. In this review, we will examine key aspects of the evolution of prostate cancer vaccines, which provides an accurate prototype for other cancers, and the challenges we face.
Insights
The first therapeutic cancer vaccine, sipuleucel-T, was approved in 2010 for prostate cancer. This review examines the evolution of prostate cancer vaccines as a model for other cancers and discusses challenges.
Area of Science:
- Oncology
- Immunology
- Vaccinology
Background:
- Prostate cancer serves as an excellent model for therapeutic cancer vaccine development.
- The slow progression of prostate cancer allows for sustained vaccine therapy and robust antitumor responses.
- Established humoral and cellular immunity to cancer antigens in prostate cancer supports vaccine strategies.
Purpose of the Study:
- To review the evolution of therapeutic cancer vaccines for prostate cancer.
- To highlight prostate cancer vaccines as a prototype for other cancer types.
- To discuss the challenges and future directions in cancer vaccine development.
Main Methods:
- Review of historical data and clinical trial outcomes for prostate cancer vaccines.
- Analysis of immunological responses to cancer vaccines in prostate cancer patients.
- Examination of the role of biomarkers in assessing vaccine efficacy.
Main Results:
- Sipuleucel-T, the first therapeutic cancer vaccine, was approved in 2010 for castration-refractory prostate cancer.
- Prostate cancer exhibits characteristics favorable for vaccine therapy, including demonstrable immune responses and slow progression.
- Serum cancer biomarkers aid in evaluating treatment response and stratifying patient risk.
Conclusions:
- Prostate cancer vaccine development offers valuable insights and a prototype for broader cancer vaccine research.
- Continued research is essential to overcome challenges and advance the field of therapeutic cancer vaccines.
- The integration of immunological understanding and clinical application is key to successful cancer vaccine strategies.
Related Concept Videos
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy
Vaccines
Cancer Prevention
Some...
Vaccinations
Targeted Cancer Therapies
There are several types of targeted therapies against specific...

